Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

BACKGROUND: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monot...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Cancer Commun (Lond)
Główni autorzy: Huang, Jing, Xu, Binghe, Liu, Ying, Huang, Junxing, Lu, Ping, Ba, Yi, Wu, Lin, Bai, Yuxian, Zhang, Shu, Feng, Jifeng, Cheng, Ying, Li, Jie, Wen, Lu, Yuan, Xianglin, Ma, Changwu, Hu, Chunhong, Fan, Qingxia, Wang, Xi
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2019
Hasła przedmiotowe:
Original Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444575/
https://ncbi.nlm.nih.gov/pubmed/30940189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0359-7
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy